Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specializing in life sciences, with a focus on healthcare and sustainability. Founded in 1972 and based in Paris, London, and Milan, it manages over €4 billion in assets and has backed more than 500 companies.
Sofinnova Partners is a Paris venture capital firm with €4.0B AUM, 107 active companies and 40 exits.
- ·17 exits in the last 5 years · consistent DPI cadence.
- ·Average hold across 40 realized deals: 4 years.
- ·Top sector focus: Biotech (71% of portfolio).
- ·Fund cadence: ~1Y between vintages · last raise 2025.
Sector breakdown
147 companiesGeography breakdown
19 geographiesKey facts
Recent exits
Sofinnova Partners sold Myricx Bio to Novartis in 2026 after 4 years.
Sofinnova Partners sold Hookipa Pharma to Gilead Sciences in 2025 after 6 years.
Sofinnova Partners sold PinCell to Scinai Immunotherapeutics in 2025 after 6 years.
Sofinnova Partners sold Sphere Bio (formerly Sphere Fluidics) to Fluidic Analytics in 2025 after 4 years.
Coverage notes
13 funds tracked, 147 portfolio companies (107 active · 40 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Sofinnova Partners has raised, with its portfolio companies. Hand-checked from public filings.
Sofinnova Biovelocita IILife Sciences VC2025€100M1 assetsLife Sciences VC2025 · 1yr€100M1–
Unrealized
1 held| Company | Entry |
|---|---|
| Signadori Bio Biotech · Italy | 2025 |
Sofinnova Capital XILife Sciences VC2025€650M2 assetsLife Sciences VC2025 · 1yr€650M2–
Unrealized
2 held| Company | Entry |
|---|---|
| Actithera Biotech · France | 2025 |
| Bionyra Pharma Biotech · France | 2025 |
Sofinnova Biovelocita ILife Sciences VC2022€50M2 assetsLife Sciences VC2022 · 4yr€50M2–
Unrealized
2 held| Company | Entry |
|---|---|
| BioClec Biotech · Italy | 2023 |
| Forth Therapeutics Biotech · Italy | 2023 |
Sofinnova Digital Medicine IVC2022€100M9 assets1 exitsVC2022 · 4yr€100M91
Unrealized
9 held| Company | Entry |
|---|---|
| BioCorteX HealthTech · UK | 2022 |
| Bioptimus Biotech · France | 2024 |
| Cure51 HealthTech · France | 2024 |
| deepc HealthTech · Germany | 2021 |
| Excelsior Sciences HealthTech · US | 2025 |
| Ingenix AI/ML · Poland | 2026 |
| Kiro HealthTech · France | 2023 |
| L'école AI HealthTech · Canada | 2023 |
| Latent Labs HealthTech · UK | 2025 |
Realized
1 exit| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| Betteromics HealthTech · US | 2022 | 2024 | Trade Sale | Apple | – |
Sofinnova Capital XLife Sciences VC2021€472M26 assets2 exitsLife Sciences VC2021 · 5yr€472M262
Unrealized
26 held| Company | Entry |
|---|---|
| Catamaran Bio Biotech · US | 2022 |
| DISCO Pharmaceuticals Biotech · Germany | 2023 |
| Elevara Medicines Biotech · UK | 2022 |
| Enthera Pharmaceuticals Biotech · Italy | 2022 |
| Freya Biosciences Biotech · Denmark | 2023 |
| Galvanize MedTech · US | 2022 |
| GlycoEra Biotech · Switzerland | 2021 |
| Haya Therapeutics Biotech · Switzerland | 2021 |
| Home Biosciences Biotech · France | 2022 |
| Inspirna Biotech · US | 2021 |
| May Health MedTech · France | 2023 |
| Mediar Therapeutics Biotech · US | 2021 |
| Mironid Biotech · UK | 2021 |
| Mnemo Therapeutics Biotech · France | 2021 |
| Mozart Therapeutics Biotech · US | 2021 |
| Muna Therapeutics Biotech · Denmark | 2021 |
| NanoPhoria Biotech · Italy | 2022 |
| Neurent Medical MedTech · Ireland | 2021 |
| NodThera Biotech · UK | 2021 |
| Nuage Therapeutics Biotech · Spain | 2023 |
| Purespring Biotech · UK | 2021 |
| Redona Therapeutics Biotech · UK | 2022 |
| Sitryx Therapeutics Biotech · UK | 2021 |
| T-Therapeutics Biotech · UK | 2023 |
| Tenpoint Therapeutics Biotech · US | 2022 |
| Werewool Biotech · US | 2022 |
Realized
2 exits| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| Mablink Bioscience Biotech · France | 2022 | 2023 | Trade Sale | Eli Lilly | – |
| Myricx Bio Biotech · UK | 2022 | 2026 | Trade Sale | Novartis | – |
Sofinnova Capital IXLife Sciences VC2018€333M20 assets5 exitsLife Sciences VC2018 · 8yr€333M205
Unrealized
20 held| Company | Entry |
|---|---|
| Asceneuron Biotech · Switzerland | 2020 |
| Comet Biorefining Biotech · Canada | 2019 |
| CorVent Medical MedTech · US | 2020 |
| CorWave MedTech · France | 2019 |
| Crescendo Biologics Biotech · UK | 2018 |
| Genespire Biotech · Italy | 2020 |
| HotSpot Therapeutics Biotech · US | 2019 |
| Inotrem Biotech · France | 2019 |
| iOmx Therapeutics Biotech · Germany | 2018 |
| Mainstay Medical MedTech · Ireland | 2018 |
| Mission Therapeutics Biotech · UK | 2019 |
| Moon Surgical MedTech · France | 2019 |
| Nitrase Therapeutics Biotech · US | 2020 |
| Pi-Cardia MedTech · Israel | 2020 |
| ProQR Therapeutics Biotech · Netherlands | 2018 |
| Pyrowave Industrials · Canada | 2020 |
| Quince Therapeutics (formerly EryDel) Biotech · US | 2019 |
| RefleXion Medical MedTech · US | 2019 |
| SafeHeal MedTech · France | 2019 |
| Tissium MedTech · France | 2018 |
Realized
5 exits| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| CinCor Pharma Biotech · US | 2019 | 2023 | Trade Sale | AstraZeneca | – |
| Hookipa Pharma Biotech · Austria | 2019 | 2025 | Trade Sale | Gilead Sciences | – |
| Noema Pharma Biotech · Switzerland | 2020 | 2022 | Trade Sale | NOEMA PHARMA SA | – |
| PinCell Biotech · Italy | 2019 | 2025 | Trade Sale | Scinai Immunotherapeutics | – |
| Shockwave Medical MedTech · US | 2018 | 2024 | Trade Sale | Johnson & Johnson | – |
Sofinnova Crossover Fund IVC2018€549M11 assets4 exitsVC2018 · 8yr€549M114
Unrealized
11 held| Company | Entry |
|---|---|
| Abivax Biotech · France | 2018 |
| Artios Pharma Biotech · UK | 2020 |
| CellCentric Biotech · United Kingdom | 2026 |
| F2G Biotech · UK | 2019 |
| GenSight Biologics Biotech · France | – |
| Hemab Therapeutics Biotech · Denmark | 2020 |
| Inventiva Biotech · France | 2019 |
| MaxCyte Biotech · US | 2019 |
| Redx Pharma Biotech · UK | 2019 |
| Sensorion Biotech · France | 2018 |
| Synthace Biotech · UK | 2019 |
Realized
4 exits| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| Amolyt Pharma Biotech · France | 2021 | 2024 | Trade Sale | AstraZeneca | – |
| Calliditas Biotech · Sweden | 2020 | 2024 | Trade Sale | Asahi Kasei | – |
| Sphere Bio (formerly Sphere Fluidics) MedTech · UK | 2021 | 2025 | Trade Sale | Fluidic Analytics | – |
| Verona Pharma Biotech · UK | 2019 | 2025 | Trade Sale | Merck (MSD) | – |
Sofinnova Industrial BiotechVC2018€200M21 assets2 exitsVC2018 · 8yr€200M212
Unrealized
21 held| Company | Entry |
|---|---|
| Afyren Biotech · France | 2019 |
| Arzeda Biotech · US | 2022 |
| Biosyntia Biotech · Denmark | 2018 |
| Biotalys Biotech · Belgium | 2019 |
| CelluComp Industrials · UK | 2015 |
| DMC Biotechnologies Biotech · US | 2019 |
| DNA Script Biotech · France | 2017 |
| Elicit Plant AgTech · France | 2019 |
| EnginZyme Biotech · Sweden | 2019 |
| Enobraq Business Services · France | 2019 |
| GFBiochemicals Biotech · France | 2016 |
| Meiogenix Biotech · France | 2019 |
| MetGen Biotech · Finland | 2017 |
| Micropep Technologies AgTech · France | 2019 |
| Microphyt Biotech · France | 2019 |
| Novameat Biotech · Spain | 2021 |
| P2 Science Industrials · United States | 2026 |
| Prometheus Materials Biotech · US | 2022 |
| Protera Biotech · US | 2020 |
| Qorium Biotech · Netherlands | 2021 |
| Verley (formerly Bon Vivant) Biotech · France | 2021 |
Realized
2 exits| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| Avantium Industrials · Netherlands | 2016 | 2017 | IPO | – | – |
| IB Works I Software · France | 2022 | 2024 | – | – | – |
Sofinnova TelethonLife Sciences VC2016€50M5 assetsLife Sciences VC2016 · 10yr€50M5–
Unrealized
5 held| Company | Entry |
|---|---|
| AAVantgarde Bio Biotech · Italy | 2020 |
| Alia Therapeutics Biotech · Italy | 2021 |
| Borea Therapeutics Biotech · Italy | 2021 |
| nChroma (formerly Chroma Medicine) Biotech · US | 2022 |
| Nephris Biotech · Italy | 2022 |
Sofinnova Capital VIIILife Sciences VC2015€300M4 assets7 exitsLife Sciences VC2015 · 11yr€300M47
Unrealized
4 held| Company | Entry |
|---|---|
| BiovelocITA Biotech · Italy | 2015 |
| ENYO Pharma Biotech · France | 2016 |
| HighLife MedTech · France | 2015 |
| NuCana Biotech · UK | 2015 |
Realized
7 exits| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| Breath Therapeutics Biotech · Germany | 2016 | 2019 | Trade Sale | Zambon | – |
| Corvidia Therapeutics Biotech · US | 2016 | 2020 | Trade Sale | Novo Nordisk | – |
| Delinia Biotech · UK | 2016 | 2017 | Trade Sale | Celgene | – |
| Lysogene Biotech · France | 2015 | 2018 | – | – | – |
| ObsEva Biotech · Switzerland | 2015 | 2017 | IPO | – | – |
| ReCor Medical MedTech · US | 2016 | 2018 | Trade Sale | Otsuka Holdings | – |
| VectivBio Biotech · Switzerland | 2017 | 2023 | Trade Sale | Ironwood Pharmaceuticals | – |
Sofinnova Capital VIILife Sciences VC2012€240M0 assets5 exitsLife Sciences VC2012 · 14yr€240M05
Realized
5 exits| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| Advanced Perfusion Diagnostics MedTech · France | 2012 | 2019 | Trade Sale | Vygon | – |
| Ascendis Pharma Biotech · Denmark | 2012 | 2015 | IPO | – | – |
| EOS Biotech · Italy | 2012 | 2013 | Trade Sale | Clovis Oncology | – |
| GlycoVaxyn Biotech · Switzerland | 2012 | 2015 | Trade Sale | GSK | – |
| Pixium Vision MedTech · France | 2013 | 2024 | Trade Sale | Science Corporation | – |
Sofinnova MD StartVC2010€30M6 assets2 exitsVC2010 · 16yr€30M62
Unrealized
6 held| Company | Entry |
|---|---|
| BrightHeart MedTech · France | 2022 |
| Endoron Medical MedTech · France | 2021 |
| Gradient Denervation Technologies MedTech · US | 2023 |
| HEPTA Medical MedTech · France | 2022 |
| Julier Medical MedTech · France | 2023 |
| Tulyp Medical MedTech · France | 2022 |
Sofinnova Capital VILife Sciences VC2008€260M0 assets12 exitsLife Sciences VC2008 · 18yr€260M012
Realized
12 exits| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| ABIONYX Pharma Biotech · France | 2010 | 2020 | IPO | – | – |
| Ablynx NV Biotech · Belgium | 2008 | 2018 | Trade Sale | Sanofi | – |
| Addex Therapeutics Biotech · Switzerland | 2008 | 2012 | – | – | – |
| CoreValve MedTech · France | 2007 | 2009 | Trade Sale | Medtronic | – |
| DBV Biotech · France | 2010 | 2014 | IPO | – | – |
| Genset Biotech · France | 1989 | 2002 | Trade Sale | Serono | – |
| Innate Pharma Biotech · France | 2000 | 2006 | IPO | – | – |
| Movetis Biotech · Belgium | 2008 | 2010 | Trade Sale | Shire | – |
| Novexel Biotech · France | 2006 | 2010 | Trade Sale | AstraZeneca | – |
| Noxxon Pharma Biotech · Germany | 2008 | 2016 | IPO | – | – |
| Omthera Pharmaceuticals Biotech · US | 2010 | 2013 | Trade Sale | AstraZeneca | – |
| PregLem Biotech · Switzerland | 2006 | 2010 | Trade Sale | Gedeon Richter | – |
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialised in life sciences with €4.0 billion of assets under management as of December 2024, headquartered in Paris with additional offices in London and Milan. Founded in 1972, the firm has backed more than 600 life sciences companies over a 53-year track record across multiple biotech, MedTech and HealthTech cycles. Sofinnova focuses exclusively on healthcare and sustainability themes, distinguishing the platform from generalist VC firms.
Investment thesis
Sofinnova deploys capital across complementary life sciences strategies including Biotech (drug discovery and development), MedTech (medical devices and digital health), HealthTech (digital health platforms) and selective Industrial Biotech and Sustainability themes. Investment stages span early-stage seed and Series A through growth equity and pre-IPO commitments, with equity tickets typically ranging from €5 million to €50 million per transaction. The platform's sector-exclusive focus enables deep scientific and clinical expertise across translational research, regulatory navigation and commercial scale-up.
Recent activity
Recent realised exits include PinCell (biotech, 2025), Verona Pharma (biotech, 2025), Amolyt Pharma (biotech, 2024), Betteromics (HealthTech, 2024) and Calliditas (biotech, 2024), reflecting strong distribution momentum across the biotech franchise. The platform tracks 13 funds, 107 active portfolio companies and 36 realised exits across a multi-decade track record.
Frequently asked questions
- What investment strategy does Sofinnova Partners focus on?
- Sofinnova Partners focuses on VC, Growth strategies in the private equity space.
- How many portfolio companies does Sofinnova Partners have?
- Sofinnova Partners has 107 active portfolio companies and 40 completed exits and 13 funds tracked on GP Intel.
- Where is Sofinnova Partners headquartered?
- Sofinnova Partners is headquartered in Paris, France.
- What is Sofinnova Partners's assets under management?
- Sofinnova Partners manages approximately €4.0B in assets under management.
- When was Sofinnova Partners founded?
- Sofinnova Partners was founded in 1997.
- What sectors does Sofinnova Partners invest in?
- Sofinnova Partners invests across Healthcare, Industrials.
- What are Sofinnova Partners's recent exits?
- Recent realized exits by Sofinnova Partners include: Myricx Bio (2026) to Novartis; Hookipa Pharma (2025) to Gilead Sciences; PinCell (2025) to Scinai Immunotherapeutics; Sphere Bio (formerly Sphere Fluidics) (2025) to Fluidic Analytics; Verona Pharma (2025) to Merck (MSD); Betteromics (2024) to Apple; Shockwave Medical (2024) to Johnson & Johnson; Amolyt Pharma (2024) to AstraZeneca.
Similar firms
Other private equity firms tracked on GP Intel.
France·€4.0B
France·€4.2B
France·€4.3B
France·€5.0B
France·€3.0B
France·€2.8B
France·€2.6B
France·€2.5B
France·€2.5B
France·€2.5B
France·€2.4B
France·€2.3B